How it works: Sorafenib inhibits multiple intracellular and vascular tyrosine kinases, blocking both tumour cell proliferation and angiogenesis (the growth of new blood vessels).
Who it’s for:
– Patients with hepatocellular carcinoma (HCC)
– Those diagnosed with renal cell carcinoma (RCC)
– Individuals with differentiated thyroid cancer resistant to radioactive iodine
– Those requiring oral, systemic, and targeted treatment
– Hepatocellular carcinoma (liver cancer)
– Renal cell carcinoma (kidney cancer)
– Differentiated thyroid cancer resistant to radioactive iodine
AASAB tablets are taken orally, typically at a dose of 400 mg per day (two 200 mg tablets twice daily), preferably on an empty stomach or 1–2 hours after meals. Dosage and duration are determined individually by the oncologist based on stage and patient condition.
Not recommended for patients with hypersensitivity to sorafenib, during pregnancy, or with severe liver dysfunction.
Possible side effects include rash, diarrhoea, high blood pressure, fatigue, and appetite loss. Medical monitoring is essential during therapy.
